Search

Your search keyword '"Baldassarre, Lauren"' showing total 287 results
Start Over Author "Baldassarre, Lauren"
287 results on '"Baldassarre, Lauren"'

1. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.

Author

Avula, Vennela, Sharma, Garima, Kosiborod, Mikhail N, Vaduganathan, Muthiah, Neilan, Tomas G, Lopez, Teresa, Dent, Susan, Baldassarre, Lauren, Scherrer-Crosbie, Marielle, Barac, Ana, Liu, Jennifer, Deswal, Anita, Khadke, Sumanth, Yang, Eric H, Ky, Bonnie, Lenihan, Daniel, Nohria, Anju, Dani, Sourbha S, and Ganatra, Sarju

Abstract

Certain antineoplastic therapies are associated with an increased risk of cardiomyopathy and heart failure (HF). Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in patients with HF.This study aims to examine the efficacy of SGLT2 inhibitors in patients with cancer therapy-related cardiac dysfunction (CTRCD) or HF.The authors conducted a retrospective cohort analysis of deidentified, aggregate patient data from the TriNetX research network. Patients aged ≥18 years with a history of type 2 diabetes mellitus, cancer, and exposure to potentially cardiotoxic antineoplastic therapies, with a subsequent diagnosis of cardiomyopathy or HF between January 1, 2013, and April 30, 2020, were identified. Patients with ischemic heart disease were excluded. Patients receiving guideline-directed medical therapy were divided into 2 groups based on SGLT2 inhibitor use. After propensity score matching, odds ratios (ORs) and Cox proportional HRs were used to compare outcomes over a 2-year follow-up period.The study cohort included 1,280 patients with CTRCD/HF (n = 640 per group; mean age: 67.6 years; 41.6% female; 68% White). Patients on SGLT2 inhibitors in addition to conventional guideline-directed medical therapy had a lower risk of acute HF exacerbation (OR: 0.483 [95% CI: 0.36-0.65]; P < 0.001) and all-cause mortality (OR: 0.296 [95% CI: 0.22-0.40]; P = 0.001). All-cause hospitalizations or emergency department visits (OR: 0.479; 95% CI: 0.383-0.599; P < 0.001), atrial fibrillation/flutter (OR: 0.397 [95% CI: 0.213-0.737]; P = 0.003), acute kidney injury (OR: 0.486 [95% CI: 0.382-0.619]; P < 0.001), and need for renal replacement therapy (OR: 0.398 [95% CI: 0.189-0.839]; P = 0.012) were also less frequent in patients on SGLT2 inhibitors.SGLT2 inhibitor use is associated with improved outcomes in patients with CTRCD/HF.

Published
2023

3. Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS).

Author

Lopez-Mattei, Juan, Yang, Eric H, Baldassarre, Lauren A, Agha, Ali, Blankstein, Ron, Choi, Andrew D, Chen, Marcus Y, Meyersohn, Nandini, Daly, Ryan, Slim, Ahmad, Rochitte, Carlos, Blaha, Michael, Whelton, Seamus, Dzaye, Omar, Dent, Susan, Milgrom, Sarah, Ky, Bonnie, Iliescu, Cezar, Mamas, Mamas A, and Ferencik, Maros

Abstract

Cardio-Oncology is a rapidly growing sub-specialty of medicine, however, there is very limited guidance on the use of cardiac CT (CCT) in the care of Cardio-Oncology patients. In order to fill in the existing gaps, this Expert Consensus statement comprised of a multidisciplinary collaboration of experts in Cardiology, Radiology, Cardiovascular Multimodality Imaging, Cardio-Oncology, Oncology and Radiation Oncology aims to summarize current evidence for CCT applications in Cardio-Oncology and provide practice recommendations for clinicians.

Published
2023

4. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.

Author

Nowatzke, Joseph, Guedeney, Paul, Palaskas, Nicholas, Lehmann, Lorenz, Ederhy, Stephane, Zhu, Han, Cautela, Jennifer, Francis, Sanjeev, Courand, Pierre-Yves, Deswal, Anita, Ewer, Steven, Aras, Mandar, Arangalage, Dimitri, Ghafourian, Kambiz, Fenioux, Charlotte, Finke, Daniel, Peretto, Giovanni, Zaha, Vlad, Itzhaki Ben Zadok, Osnat, Tajiri, Kazuko, Akhter, Nausheen, Levenson, Joshua, Baldassarre, Lauren, Salem, Joe-Elie, Huang, Shi, Collet, Jean-Philippe, Power, John, and Moslehi, Javid

Subjects
Acute coronary syndrome, Coronary revascularization, Immune checkpoint blockers, Immune-related adverse events, Myocarditis, Humans, Coronary Artery Disease, Immune Checkpoint Inhibitors, Retrospective Studies, Myocarditis, Prognosis, Registries, Risk Factors
Abstract

PURPOSE: Immune checkpoint blocker (ICB) associated myocarditis (ICB-myocarditis) may present similarly and/or overlap with other cardiac pathology including acute coronary syndrome presenting a challenge for prompt clinical diagnosis. METHODS: An international registry was used to retrospectively identify cases of ICB-myocarditis. Presence of coronary artery disease (CAD) was defined as coronary artery stenosis >70% in patients undergoing coronary angiogram. RESULTS: Among 261 patients with clinically suspected ICB-myocarditis who underwent a coronary angiography, CAD was present in 59/261 patients (22.6%). Coronary revascularization was performed during the index hospitalisation in 19/59 (32.2%) patients. Patients undergoing coronary revascularization less frequently received steroids administration within 24 h of admission compared to the other groups (p = 0.029). Myocarditis-related 90-day mortality was 9/17 (52.7%) in the revascularised cohort, compared to 5/31 (16.1%) in those not revascularized and 25/156 (16.0%) in those without CAD (p = 0.001). Immune-related adverse event-related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 6/31 (19.4%) in those not revascularized and 31/156 (19.9%) in no CAD groups (p = 0.007). All-cause 90-day mortality was 11/17 (64.7%) in the revascularized cohort, compared to 13/31 (41.9%) in no revascularization and 60/158 (38.0%) in no CAD groups (p = 0.10). After adjustment of age and sex, coronary revascularization remained associated with ICB-myocarditis-related death at 90 days (hazard ratio [HR] = 4.03, 95% confidence interval [CI] 1.84-8.84, p

Published
2022

5. Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review.

Author

Baldassarre, Lauren A, Ganatra, Sarju, Lopez-Mattei, Juan, Yang, Eric H, Zaha, Vlad G, Wong, Timothy C, Ayoub, Chadi, DeCara, Jeanne M, Dent, Susan, Deswal, Anita, Ghosh, Arjun K, Henry, Mariana, Khemka, Abhishek, Leja, Monika, Rudski, Lawrence, Villarraga, Hector R, Liu, Jennifer E, Barac, Ana, and Scherrer-Crosbie, Marielle

Abstract

The population of patients with cancer is rapidly expanding, and the diagnosis and monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in the field of cardio-oncology and imaging have occurred in recent years. This review presents updated and practical approaches for multimodality cardiovascular imaging in the cardio-oncology patient and provides recommendations for imaging to detect the myriad of adverse cardiovascular effects associated with antineoplastic therapy, such as cardiomyopathy, atherosclerosis, vascular toxicity, myocarditis, valve disease, and cardiac masses. Uniquely, we address the role of cardiovascular imaging in patients with pre-existing cardiomyopathy, pregnant patients, long-term survivors, and populations with limited resources. We also address future avenues of investigation and opportunities for artificial intelligence applications in cardio-oncology imaging. This review provides a uniform practical approach to cardiovascular imaging for patients with cancer.

Published
2022

6. Impact of Social Vulnerability on Comorbid Cancer and Cardiovascular Disease Mortality in the United States.

Author

Ganatra, Sarju, Dani, Sourbha S, Kumar, Ashish, Khan, Safi U, Wadhera, Rishi, Neilan, Tomas G, Thavendiranathan, Paaladinesh, Barac, Ana, Hermann, Joerg, Leja, Monika, Deswal, Anita, Fradley, Michael, Liu, Jennifer E, Sadler, Diego, Asnani, Aarti, Baldassarre, Lauren A, Gupta, Dipti, Yang, Eric, Guha, Avirup, Brown, Sherry-Ann, Stevens, Jennifer, Hayek, Salim S, Porter, Charles, Kalra, Ankur, Baron, Suzanne J, Ky, Bonnie, Virani, Salim S, Kazi, Dhruv, Nasir, Khurram, and Nohria, Anju

Abstract

Racial and social disparities exist in outcomes related to cancer and cardiovascular disease (CVD).The aim of this cross-sectional study was to study the impact of social vulnerability on mortality attributed to comorbid cancer and CVD.The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database (2015-2019) was used to obtain county-level mortality data attributed to cancer, CVD, and comorbid cancer and CVD. County-level social vulnerability index (SVI) data (2014-2018) were obtained from the CDC's Agency for Toxic Substances and Disease Registry. SVI percentiles were generated for each county and aggregated to form SVI quartiles. Age-adjusted mortality rates (AAMRs) were estimated and compared across SVI quartiles to assess the impact of social vulnerability on mortality related to cancer, CVD, and comorbid cancer and CVD.The AAMR for comorbid cancer and CVD was 47.75 (95% CI: 47.66-47.85) per 100,000 person-years, with higher mortality in counties with greater social vulnerability. AAMRs for cancer and CVD were also significantly greater in counties with the highest SVIs. However, the proportional increase in mortality between the highest and lowest SVI counties was greater for comorbid cancer and CVD than for either cancer or CVD alone. Adults

Published
2022

7. Artificial Intelligence and Machine Learning for Cardiovascular Computed Tomography (CCT): A White Paper of the Society of Cardiovascular Computed Tomography (SCCT)

Author

Williams, Michelle C., Weir-McCall, Jonathan R., Baldassarre, Lauren A., De Cecco, Carlo N., Choi, Andrew D., Dey, Damini, Dweck, Marc R., Isgum, Ivana, Kolossvary, Márton, Leipsic, Jonathon, Lin, Andrew, Lu, Michael T., Motwani, Manish, Nieman, Koen, Shaw, Leslee, van Assen, Marly, and Nicol, Edward

Published
2024
Full Text
View/download PDF

8. Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer.

Author

Lopez-Mattei, Juan C, Yang, Eric H, Ferencik, Maros, Baldassarre, Lauren A, Dent, Susan, and Budoff, Matthew J

Abstract

Cancer patients and survivors have elevated cardiovascular risk when compared with noncancer patients. Cardio-oncology has emerged as a new subspecialty to comanage and address cardiovascular complications in cancer patients such as heart failure, atherosclerotic cardiovascular disease (ASCVD), valvular heart disease, pericardial disease, and arrhythmias. Cardiac computed tomography (CT) can be helpful in identifying both clinical and subclinical ASCVD in cancer patients and survivors. Radiation therapy treatment planning CT scans and cancer staging/re-staging imaging studies can quantify calcium scores which can identify pre-existing subclinical ASCVD. Cardiac CT can be helpful in the evaluation of cardiac tumors and pericardial diseases, especially in patients who cannot tolerate or have a contraindication to cardiac magnetic resonance. In this review, we describe the optimal utilization of cardiac CT in cancer patients, including risk assessment for ASCVD and identification of cancer treatment-related cardiovascular toxicity.

Published
2021

11. Multimodality Cardiac Imaging and the Imaging Workforce in the United States: Diversity, Disparities, and Future Directions

Author

Bullock-Palmer, Renee P., Flores Rosario, Karen, Douglas, Pamela S., Hahn, Rebecca T., Lang, Roberto M., Chareonthaitawee, Panithaya, Srichai, Monvadi B., Ordovas, Karen G., Baldassarre, Lauren A., Burroughs, Melissa S., Henderson, Cory S., Woodard, Pamela K., Pressoir, Kathleen, Swaminathan, Madhav, Blankstein, Ron, and Daubert, Melissa A.

Published
2024
Full Text
View/download PDF

14. Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey

Author

Sadler, Diego, DeCara, Jeanne M, Herrmann, Joerg, Arnold, Anita, Ghosh, Arjun K, Abdel-Qadir, Husam, Yang, Eric H, Szmit, Sebastian, Akhter, Nausheen, Leja, Monika, Silva, Carolina Maria Pinto Domingues Carv, Raikhelkar, Jayant, Brown, Sherry-Ann, Dent, Susan, O’Quinn, Rupal, Thuny, Franck, Moudgil, Rohit, Raez, Luis E, Okwuosa, Tochukwu, Daniele, Andres, Bauer, Brenton, Kondapalli, Lavanya, Ismail-Khan, Roohi, Lax, Jorge, Blaes, Anne, Nahleh, Zeina, Elson, Leah, Baldassarre, Lauren A, Zaha, Vlad, Rao, Vijay, Lara, Daniel Sierra, Skurka, Kerry, and on behalf of the Cardio-Oncology International Collaborative Network

Published
2020

15. Cardiovascular care of the oncology patient during COVID-19: An expert consensus document from the ACC Cardio-Oncology and Imaging Councils.

Author

Baldassarre, Lauren A, Yang, Eric H, Cheng, Richard K, DeCara, Jeanne M, Dent, Susan, Liu, Jennifer E, Rudski, Lawrence G, Strom, Jordan B, Thavendiranathan, Paaladinesh, Barac, Ana, Zaha, Vlad G, Bucciarelli-Ducci, Chiara, Ellahham, Samer, Deswal, Anita, Lenneman, Carrie, Villarraga, Hector R, Blaes, Anne H, Ismail-Khan, Roohi, Ky, Bonnie, Leja, Monika J, and Scherrer-Crosbie, Marielle

Abstract

In response to the coronavirus disease 2019 (COVID-19) pandemic, The Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this expert consensus statement. Cardio-oncology patients-individuals with an active or prior cancer history, and with or at risk of cardiovascular disease-are a rapidly growing population, who are both at increased risk of infection by COVID-19 and experiencing severe and/or lethal complications. Recommendations for optimizing screening and monitoring visits to detect cardiac dysfunction are discussed. In addition, judicious use of multimodality imaging and biomarkers are proposed to identify myocardial, valvular, vascular, pericardial involvement in cancer patients. The difficulties of diagnosing the etiology of cardiovascular complications in patients with cancer and COVID-19 are outlined, along with weighing the advantages against risks of exposure, with the modification of existing cardiovascular treatments and cardiotoxicity surveillance in patients with cancer during the COVID-19 pandemic.

Published
2020

16. Myocardial Injury on CMR in Patients With COVID-19 and Suspected Cardiac Involvement

Author

Vidula, Mahesh K., Rajewska-Tabor, Justyna, Cao, J. Jane, Kang, Yu, Craft, Jason, Mei, Winifred, Chandrasekaran, Preethi S., Clark, Daniel E., Poenar, Ana-Maria, Gorecka, Miroslawa, Malahfji, Maan, Cowan, Eilidh, Kwan, Jennifer M., Reinhardt, Samuel W., Al-Tabatabaee, Sarah, Doeblin, Patrick, Villa, Adriana D.M., Karagodin, Ilya, Alvi, Nazia, Christia, Panagiota, Spetko, Nicholas, Cassar, Mark Philip, Park, Christine, Nambiar, Lakshmi, Turgut, Alper, Azad, Mahan Roosta, Lambers, Moritz, Wong, Timothy C., Salerno, Michael, Kim, Jiwon, Elliott, Michael, Raman, Betty, Neubauer, Stefan, Tsao, Connie W., LaRocca, Gina, Patel, Amit R., Chiribiri, Amedeo, Kelle, Sebastian, Baldassarre, Lauren A., Shah, Dipan J., Hughes, Sean G., Tong, Matthew S., Pyda, Malgorzata, Simonetti, Orlando P., Plein, Sven, and Han, Yuchi

Published
2023
Full Text
View/download PDF

18. Abstract 12012: Adverse Social Determinants of Health Are Associated With Increased Risk of Uncontrolled Hypertension Among Cancer Patients in Rural Georgia: A Prospective Cohort Study

Author

Nain, Priyanshu, Stabellini, Nickolas, Yerraguntla, Sandeep, Gopu, Gaurav, Bhave, Aditya, Seth, Lakshya, Patel, Vraj, Jiang, Stephanie, Malik, Sarah, Weintraub, Neal L, Montero, Alberto J, Fofanah, Alusine, Cullen, Jennifer, Agarwal, Neeraj, Wang, Xiaoling, Ky, Bonnie, Baldassarre, Lauren A, Harris, Ryan A, and Guha, Avirup

Published
2023
Full Text
View/download PDF

19. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry

Author

Aghel, Nazanin, Alexandre, Joachim, Aonuma, Kazutaka, Asnani, Aarti H., Behling, Juliane, Bilen, Mehmet, Bottinor, Wendy, Cariou, Eve, Chahine, Johnny, Chan, Weiting, Chauhan, Aman, Cohen, Max, Crusz, Shanthini, Fernando, Suran, Florido, Roberta, Frigeri, Mauro, Fukushima, Satoshi, Gaughan, Elizabeth, Geisler, Benjamin P., Gilstrap, Lauren, Grohe, Christian, Guha, Avirup, Habib, Manhal, Haegler-Laube, Eva, Haydon, Andrew, Hayek, Salim, Hughes, Andrew, Imai, Rysk, Katsume, Yumi, Kimura, Hideki, Koo Lin, Lily, Lenneman, Carrie, Leong, Daryl, Makker, Vicky, Martinez-Calle, Nicolas, Moey, Melissa, Mohri, Masahiro, Morimoto, Ryota, Moritoki, Yoshinobu, Narezkina, Anna, Nicol, Martin, Nooka, Ajay, Orimoloye, Olusola, Patel, Milan, Perl, Michal, Piriou, Nicolas, Raikhelkar, Jayant K., Raza, Yasmin, Rao, Anjali, Reddy, Sunil, Seki, Nobuhiko, Stangl, Karl, Stewart, Andrew, Stringer, Bryan, Tamarappoo, Balaji K., Tamura, Yuichi, Thuny, Frank, Tierney, Sean, Tresorier, Romain, Ullah, Waqas, Von Hunolstein, Jean-Jacques, Warner, Ellen, Weppler, Allison, Nowatzke, Joseph, Guedeney, Paul, Palaskas, Nicholas, Lehmann, Lorenz, Ederhy, Stephane, Zhu, Han, Cautela, Jennifer, Francis, Sanjeev, Courand, Pierre-Yves, Deswal, Anita, Ewer, Steven M., Aras, Mandar, Arangalage, Dimitri, Ghafourian, Kambiz, Fenioux, Charlotte, Finke, Daniel, Peretto, Giovanni, Zaha, Vlad, Itzhaki Ben Zadok, Osnat, Tajiri, Kazuko, Akhter, Nausheen, Levenson, Joshua, Baldassarre, Lauren, Power, John, Huang, Shi, Collet, Jean-Philippe, Moslehi, Javid, and Salem, Joe-Elie

Published
2022
Full Text
View/download PDF

20. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis

Author

Lehmann, Lorenz H., Heckmann, Markus B., Bailly, Guillaume, Finke, Daniel, Procureur, Adrien, Power, John R., Stein, Frederic, Bretagne, Marie, Ederhy, Stephane, Fenioux, Charlotte, Hamwy, Omar, Funck-Brentano, Elisa, Romano, Emanuela, Pieroni, Laurence, Münster, Jan P., Allenbach, Yves, Anquetil, Céline, Leonard-Louis, Sarah, Palaskas, Nicolas L., Hayek, Salim S., Katus, Hugo A., Giannitsis, Evangelos, Frey, Norbert, Kaya, Ziya, Moslehi, Javid, Prifti, Edi, Salem, Joe-Elie, Thuny, Franck, Crusz, Shanthini, Asnani, Aarti, Karlstaedt, Anja, Rocher, Fanny, Paven, Elise, Obeid, Michel, Chan, Wei Ting, Flint, Danette L, Arangalage, Dimitri, Courand, Pierre-Yves, Nicol, Martin, Cariou, Eve, Tamura, Yuichi, Florido, Roberta, Francis, Sanjeev, Leong, Darryl, Piriou, Nicolas, Akhter, Nausheen, Shahneen, Sandhu, Itzhaki Ben Zadok, Osnat, Habib, Manhal, Vachhani, Pankit, Peretto, Giovanni, Zhu, Han, Laufer Perl, Michal, Aras, Mandar, Alexandre, Joachim, Lenneman, Carrie, Levenson, Joshua, Deswal, Anita, Zaha, Vlad G., Gaughan, Elizabeth M, Ewer, Steven, Johnson, Douglas, and Baldassarre, Lauren A

Published
2023
Full Text
View/download PDF

21. Adverse social determinants of health elevate uncontrolled hypertension risk: a cardio-oncology prospective cohort study.

Author

Nain, Priyanshu, Stabellini, Nickolas, Makram, Omar M, Rast, Johnathan, Yerraguntla, Sandeep, Gopu, Gaurav, Bhave, Aditya, Seth, Lakshya, Patel, Vraj, Jiang, Stephanie, Malik, Sarah, Shetewi, Ahmed, Montero, Alberto J, Cullen, Jennifer, Agarwal, Neeraj, Wang, Xiaoling, Ky, Bonnie, Baldassarre, Lauren A, Weintraub, Neal L, and Harris, Ryan A

Abstract

The role of social determinants of health (SDOH) in controlling hypertension (HTN) in cancer patients is unknown. We hypothesize that high SDOH scores correlate with uncontrolled HTN in hypertensive cancer patients. In our prospective study, patients completed the Protocol for Responding to & Assessing Patients' Assets, Risks & Experiences questionnaire. After integrating home and clinic blood pressure readings, uncontrolled HTN was defined as systolic blood pressure greater than or equal to 140 mm Hg and/or diastolic blood pressure greater than or equal to 90 mm Hg. Using Cox regression, we analyzed the impact of SDOH on HTN control, adjusting for relevant factors. The study involved 318 participants (median age 66.4, median follow-up 166 days, SDOH score 6.5 ± 3.2), with stress, educational insecurity, and social isolation as prevalent adverse SDOH. High SDOH scores led to 77% increased risk of uncontrolled HTN (adjusted hazards ratio = 1.77; 95% confidence interval = 1.10 to 2.83, P  = .018). Urban residents with high SDOH scores were at an even greater risk. Identifying SDOH and mitigating underlying factors may help control HTN, the most typical disease process treated in all cardio-oncology clinics. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Abstract 11850: Association Between SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Antineoplastic Therapy Associated Cardiomyopathy and Heart Failure

Author

Avula, Vennela, Sharma, Garima, Kosiborod, Mikhail N, Vaduganathan, Muthiah, Neilan, Tomas G, Lopez-Fernandez, Teresa, Dent, Susan F, Baldassarre, Lauren A, Scherrer-Crosbie, Marielle, Scherrer-crosbie, Marielle, Barac, Ana, Liu, Jennifer, Deswal, Anita M, Yang, Eric H, Ky, Bonnie, Lenihan, Daniel, Lenihan, Daniel, Nohria, Anju, Nohria, Anju, Dani, Sourbha, and Ganatra, Sarju

Published
2022
Full Text
View/download PDF

30. Comprehensive Characterization of Cardiac, Skeletal and Diaphragmatic Myotoxicity Using CMR in Patients with Immune Checkpoint Inhibitor Therapy and Relation to Outcomes

Author

Charpentier, Etienne, primary, boussouar, samia, additional, Bretagne, Marie, additional, Bouazizi, Khaoula, additional, Kachenoura, Nadjia, additional, Nguyen, Lan Anh, additional, Pasi, Nicoletta, additional, Edhery, Stephane, additional, allenbach, yves, additional, Similowski, Thomas, additional, Kerneis, Mathieu, additional, Baldassarre, Lauren, additional, Salem, Joe-Elie, additional, and Redheuil, Alban, additional

Published
2024
Full Text
View/download PDF

31. Prospective Evaluation of Immune Checkpoint Inhibitor Myocarditis with Serial Quantitative Cardiovascular Magnetic Resonance and Correlations with Cardiovascular Outcomes

Author

Khattab, Mohamad, primary, Kwan, Jennifer, additional, Chehayeb, Rachel Jaber, additional, Guajardo, Ana Ferrigno, additional, Lin, Derrick, additional, Christophides, Anthos, additional, Alkhatib, Deya, additional, Martinez, Carlos Matute, additional, Shah, Nimish, additional, Im, Yunju, additional, Jeyashanmugaraja, Gini Priyadharshini, additional, Ragheb, Elio, additional, Higgins, Angela, additional, Redheiul, Alban, additional, Salem, Joe-Elie, additional, Peters, Dana, additional, Mohjibian, Hamid, additional, and Baldassarre, Lauren, additional

Published
2024
Full Text
View/download PDF

33. Left Atrial Evaluation in Immune Check Point Inhibitor Myocarditis Using Cardiac Magnetic Resonance Imaging and Correlations with Cardiovascular Outcomes

Author

Jeyashanmugaraja, Gini Priyadharshini, primary, Kwan, Jennifer, additional, Shah, Nimish, additional, Lamy, Jerome, additional, Khattab, Mohamad, additional, Chehayeb, Rachel Jaber, additional, Guajardo, Ana Ferrigno, additional, Lin, Derrick, additional, Christofides, Anthos, additional, Alkhatib, Deya, additional, Martinez, Carlos Matute, additional, Im, Yunju, additional, Salem, Joe-Elie, additional, Redheuil, Alban, additional, Peters, Dana, additional, and Baldassarre, Lauren, additional

Published
2024
Full Text
View/download PDF

35. Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR)

Author

Ordovas, Karen G., Baldassarre, Lauren A., Bucciarelli-Ducci, Chiara, Carr, James, Fernandes, Juliano Lara, Ferreira, Vanessa M., Frank, Luba, Mavrogeni, Sophie, Ntusi, Ntobeko, Ostenfeld, Ellen, Parwani, Purvi, Pepe, Alessia, Raman, Subha V., Sakuma, Hajime, Schulz-Menger, Jeanette, Sierra-Galan, Lilia M., Valente, Anne Marie, and Srichai, Monvadi B.

Published
2021
Full Text
View/download PDF

37. Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy

Author

Latif, Syed R., Nguyen, Vinh Q., Peters, Dana C., Soufer, Aaron, Henry, Mariana L., Grunseich, Karl, Testani, Jeffrey, Hur, David J., Huber, Steffen, Mojibian, Hamid, Dicks, Demetrius, Sinusas, Albert J., Meadows, Judith L., Papoutsidakis, Nikolaos, Jacoby, Daniel, and Baldassarre, Lauren A.

Published
2019
Full Text
View/download PDF

42. Kiosk 5R-TB-01 - Prospective Evaluation of Immune Checkpoint Inhibitor Myocarditis with Serial Quantitative Cardiovascular Magnetic Resonance and Correlations with Cardiovascular Outcomes

Author

Khattab, Mohamad, Kwan, Jennifer, Chehayeb, Rachel Jaber, Guajardo, Ana Ferrigno, Lin, Derrick, Christophides, Anthos, Alkhatib, Deya, Martinez, Carlos Matute, Shah, Nimish, Im, Yunju, Jeyashanmugaraja, Gini Priyadharshini, Ragheb, Elio, Higgins, Angela, Redheiul, Alban, Salem, Joe-Elie, Peters, Dana, Mohjibian, Hamid, and Baldassarre, Lauren

Published
2024
Full Text
View/download PDF

43. Kiosk 5R-TA-04 - Comprehensive Characterization of Cardiac, Skeletal and Diaphragmatic Myotoxicity Using CMR in Patients with Immune Checkpoint Inhibitor Therapy and Relation to Outcomes

Author

Charpentier, Etienne, boussouar, samia, Bretagne, Marie, Bouazizi, Khaoula, Kachenoura, Nadjia, Nguyen, Lan Anh, Pasi, Nicoletta, Edhery, Stephane, allenbach, yves, Similowski, Thomas, Kerneis, Mathieu, Baldassarre, Lauren, Salem, Joe-Elie, and Redheuil, Alban

Published
2024
Full Text
View/download PDF

44. Kiosk 5R-TA-01 - Left Atrial Evaluation in Immune Check Point Inhibitor Myocarditis Using Cardiac Magnetic Resonance Imaging and Correlations with Cardiovascular Outcomes

Author

Jeyashanmugaraja, Gini Priyadharshini, Kwan, Jennifer, Shah, Nimish, Lamy, Jerome, Khattab, Mohamad, Chehayeb, Rachel Jaber, Guajardo, Ana Ferrigno, Lin, Derrick, Christofides, Anthos, Alkhatib, Deya, Martinez, Carlos Matute, Im, Yunju, Salem, Joe-Elie, Redheuil, Alban, Peters, Dana, and Baldassarre, Lauren

Published
2024
Full Text
View/download PDF

49. Scientific document development standards for the society of cardiovascular computed tomography (SCCT):A statement from the SCCT Guidelines Committee

Author

Baldassarre, Lauren A., Koweek, Lynne, Andreini, Daniele, Branch, Kelley, Brennaman, Dawn, Budde, Ricardo P.J., De La O, Stacy, Fairbairn, Timothy, Hedgire, Sandeep S., Weir-McCall, Jonathan R., Woodard, Pam K., Wong, Dennis, Chen, Marcus Y., Baldassarre, Lauren A., Koweek, Lynne, Andreini, Daniele, Branch, Kelley, Brennaman, Dawn, Budde, Ricardo P.J., De La O, Stacy, Fairbairn, Timothy, Hedgire, Sandeep S., Weir-McCall, Jonathan R., Woodard, Pam K., Wong, Dennis, and Chen, Marcus Y.

Abstract

The Society of Cardiovascular Computed Tomography (SCCT) is an international community of physicians, scientists and technologists advocating for research, education, and clinical excellence in the use of cardiovascular computed tomography (CCT). SCCT members are committed to improving health outcomes through effective use of CCT. The SCCT routinely authors, endorses, and jointly collaborates on scientific documents that reflect the best available evidence and expert consensus supported in practice of CCT. This paper outlines SCCT's methodology for developing scientific documents. It was formulated by members of the SCCT Guidelines Committee and approved by the SCCT Board of Directors.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results